Keytruda’s positive cervical cancer data: Merck said Friday that its powerhouse cancer drug reduced the risk of disease progression or death in advanced cervical cancer by 30% in Phase III study results presented at ESMO. Median progression-free survival was not reached in either arm, but PFS at 24 months was 67.8% for the newly diagnosed patients who received Keytruda on top of chemotherapy compared to 57.3% for those who received chemotherapy alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.